Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sebivo innate immune responses in chronic hepatitis B
2010-022627-29Phase 4Terminated
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Dec 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of telbivudine in Chronic Hepatitis B (CHB), sponsored by IRCCS San Matteo Foundation. Primary endpoints: Innate immune response restoration and Innate immune modulation. Started Dec 2010; status: terminated.
02
Drugs
telbivudine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2010-022627-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022627-29.